Two phase III trials evaluating ORAL serlopitant for prurigo nodularis (PN) fail to meet primary endpoint

In both studies, serlopitant failed to show a statistically significant reduction in pruritus compared to placebo based on a 4-point improvement responder analysis at week 10. Serlopitant is a neurokinin-1 (NK-1) receptor antagonist.


Biospace Inc.